anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide an electronic medical chart server or the like which is high in convenience, and improved in the efficiency of a task.SOLUTION: The medical information of a patient is displayed at terminal equipment 2 in accordance with the items of a medical chart set by a user by an in-facility server 4. A disease name search part 12 is configured to search a disease name from the medical information of the patient. A patient information acquisition part 13 is configured to acquire the medical information of the patient. An item acquisition part 14 is configured to, from user information in which the disease name, user ID, user attributes and the items of the medical chart are preliminarily associated with each other, acquire the items of the medical chart associated with the user ID input from the outside or the user attributes related to the input user ID and the searched disease name. An edition part 16 is configured to edit the acquired medical information of the patient in accordance with the acquired items, and to output it as an electronic medical chart. When any item is not set by the user, the medical information of the patient is displayed in accordance with the items set in accordance with the job classification of the user.
The present invention discloses the preparation process of microcapsule with included anticancer medicine. The process adopts colloid particle containing polyelectrolyte as template, assembles polyelectrolytes with dislike charges via layer-by-layer self-assembling to the surface of colloid particle, and dissolves or decomposes the colloid particle to obtain hollow polymer microcapsule containing polyelectrolyte. The microcapsule has wall micro structure and thickness capable of being regulated precisely in nanometer size, and the contained polyelectrolyte can interact with the medicine so as to include the medicine into the microcapsule. The included medicine has controllable release speed. Introducing polyelectrolyte with grafted polyglycol to the surface of the microcapsule can raise the biocompatibility of the microcapsule. The process of the present invention is simple, feasible and repeatable, and suitable for inclusion and controllable release of various kinds of water soluble anticancer medicine.
Viral infections are important causes of wheezing illnesses throughout childhood and in adults with asthma. There has been progress in identifying mechanisms and risk factors for severe respiratory symptoms, and in particular, wheezing. Given this close relationship, it would be attractive to apply antiviral strategies to the prevention and treatment of asthma, and both RV and RSV are obvious targets. Unfortunately, attempts at developing an RSV vaccine have so far been unsuccessful, and vaccination to prevent RV infection does not seem to be feasible due to the large number of serotypes. Antiviral medications have been tested in clinical trials, however one problem with this approach is that once the clinical signs and symptoms appear, viral replication is well underway.

The other potential therapeutic approach for respiratory viral infections would be to selectively inhibit pro-inflammatory immune responses induced by the virus. The beneficial effects of systemic glucocorticoids indicate that this approach is valid; the challenge will be to develop treatments with greater efficacy and a reduced potential for adverse effects. The large body of information linking cysteinyl leukotrienes to viral infections, allergic inflammation, and asthma exacerbations, strongly supports the hypothesis that virus-induced leukotrienes contribute to the severity of respiratory infections and in susceptible individuals, lead to lower airway obstruction and exacerbations of asthma. We propose to use montelukast in an experimental viral challenge model to explore this hypothesis.
A composition for solvating one or more active agents in an aqueous solution which is suitable for dispensing as a compressed gas aerosol composition is disclosed. The composition includes at least one surfactant, at least one active agent (such as a fragrance or an insecticide), and a compressed gas propellant. The at least one surfactant is preferably present in an amount from about 0.1 wt. % to about 3 wt. %. The at least one active agent is preferably present in an amount from about 0.1 wt. % to about 2 wt. %. The compressed gas propellant is preferably present in an amount from about 0.1 wt. % to about 1 wt. %. The total surfactant weight to active agent weight ratio for the composition is preferably about 1:3 to 5:1. The composition uses a reduced amount of surfactant and active agent thereby allowing for a more efficient active agent loading and a reduced stickiness or tackiness on surfaces contacted during use.
Each 6 gram strawberry gummy contains 45% freeze-dried fruit (California Strawberry Commission), 44% corn syrup (Karo, ACH Food Companies, Memphis, TN), 11% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL). With this formulation, daily fruit consumption is equivalent to 1 cup of whole strawberries. All ingredients (wheat starch, freeze-dried fruit, and high fructose corn syrup) will be purchased from a single lot. When a single lot is not available then the multiple manufacturing lots will be mixed into a single lot to be used for production of fruit gummies.
Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-21 of each 21-day cycle. Starting dose for dose escalation is 80 mg.
Participants randomized to the VCT only arm will not receive any further intervention. VCT will be based on on CDC guidelines and the control arms of large community-based RCTs (e.g., Projects RESPECT, EXPLORE, AWARE). VCT will consist of one 45-minute session given that 1-session VCT is as effective as 2-session VCT for GBM.
The invention relates to a nitroglycerin cavity (hypoglossis) disintegrating tablet and a preparation method which mainly adopts water-soluble excipient. When coming across saliva, a disintegrating tablet can be disintegrated rapidly and most of the excipient is dissolved, which can be absorbed into body to recycle by hypoglossis mucosa. The main indigent of the invention is nitroglycerin ethanol solution occupying 10 percent in weight, and the containing weight uses the mixture of lactose and xylitol in every 10g is 0.8 to 0.9ml. The excipient comprises microcrystalline cellulose 101, low-substituted hydroxypropyl cellulose, disintegrant, lactose, xylitol, alcoholic solution of PVP30 and magnesium stearate. The invention adopts a wet method of preparing particle and tablet, combines with blank particle method to mix the blank particles and the particles containing medicine after being made into particles, which changes the traditional method of spraying medicine layer to blank particles and raises the stability of medicine. The pressure of a tabletting machine is adjusted to 1 to 3kg and the disintegration of the pressed tablets is speeded up.
The MEAT diet will be a diet without dairy products. In this diet cheese is mainly replaced by high-fat mixed meat products to achieve saturated fat content and protein quality similar to that of the CHEESE diet. The MEAT diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
FIELD: biotechnology, veterinary science. SUBSTANCE: invention proposes medicinal form of highly purified immunologically active preparation based on hybrid protein T-TNF-T. Hybrid protein T-TNF-T is isolated from microorganism where recombinant plasmid pThy325 encoding protein biosynthesis is inserted. Preparation has the following components, wt.-%: hybrid protein 0.0008-0.0015; stabilizing additions 10-20, saline buffer system at pH = 7.0-7.2 1.03-1.06, and water - the rest. Polyglucine, gelatinol, sucrose were used as stabilizing additions and buffered sodium chloride physiological solution - as saline buffer system. Preparation can be used for nonspecific prophylaxis and treatment of infectious diseases. EFFECT: enhanced effectiveness of preparation. 3 cl, 6 tbl
Memantine induced neuronal lesions (vacuolation and necrosis) in the multipolar and pyramidal cells in cortical layers III and IV of the posterior cingulate and retrosplenial neocortices in rats, similar to those which are known to occur in rodents administered other NMDA receptor antagonists. Lesions were seen after a single dose of memantine. In a study in which rats were given daily oral doses of memantine for 14 days, the no-effect dose for neuronal necrosis was 4 times the maximum recommended human dose (MRHD of 28 mg/day) on a mg/m basis. 2

In a neurotoxicity study, female rats were given oral doses of memantine (3, 10, 30, 60 mg/kg/day) alone or in combination with donepezil (3, 10 mg/kg/day) for 28 days. When administered alone, memantine induced neurodegeneration only at 60 mg/kg/day; however, when administered in combination with 10 mg/kg/day donepezil, memantine induced neurodegeneration at doses of 30 and 60 mg/kg/day. When 60 mg/kg/day memantine and 10 mg/kg/day donepezil were administered in combination, the incidence and severity of neurodegeneration was increased compared to that with 60 mg/kg/day memantine alone or with 30 mg/kg/day memantine in combination with 10 mg/kg/day donepezil. In addition, the combination of 60 mg/kg/day memantine and 10 mg/kg/day donepezil was associated with widespread neurodegeneration in cortical areas (perirhinal, temporal, entorhinal, frontal, insular, piriform) and in olfactory nucleus and subiculum, whereas in the other affected groups, there was limited cortical (entorhinal, retrosplenial) involvement. At the no-effect level of the combination (10 mg/kg/day memantine + 10 mg/kg/day donepezil), plasma exposures of memantine were similar to (AUC) or two times (Cmax) those expected in humans at the MRHD; plasma exposures of donepezil were 3 (AUC) or 6 (Cmax) times those in humans at the MRHD of donepezil (10 mg/day). In a published study, similar donepezil-mediated exacerbation of memantine-induced neurodegeneration was observed in female rats given single doses of memantine in combination with donepezil, both administered by intraperitoneal injection.

The potential for induction of central neurodegenerative lesions by NMDA receptor antagonists in humans is unknown.
The Arthritis Self-Management Program (ASMP) will be administered to 15 African American lupus patients participating in an ongoing "SLE Clinic Database Project" at the Medical University of South Carolina (MUSC). Fifteen other patients will serve as controls and receive usual care.
Obesity and obesity-related conditions today constitute a public health problem worldwide. Obesity is an "epidemic" chronic disorder, which is defined by the WHO as normal or excessive fat accumulation that may impair health. It is also defined for adults as a BMI that is greater than or equal to 30. The most common obesity-related diseases are type 2 diabetes mellitus, cardiovascular diseases, metabolic syndrome, chronic kidney disease, hyperlipidemia, hypertension, nonalcoholic fatty liver disease, and certain types of cancer. It has been also proven that obesity can have a negative effect on hair. It can lead to hair thinning. Patients with obesity can undergo bariatric surgery if they meet the inclusion criteria. The four common types of weight loss surgery include a duodenal switch with biliopancreatic diversion, laparoscopic adjustable gastric banding, Roux-en-Y gastric bypass, and sleeve gastrectomy. Bariatric surgery can affect skin and hair and is associated with telogen effluvium due to weight loss, microelement deficiency, anesthesia, low calorie intake, and low protein intake. Patients who undergo bariatric surgery can experience post-bariatric surgery depression. Hair loss can have a major impact on self-esteem, negatively affecting one's self-image. The purpose of this narrative review is to critically review how obesity, obesity-related diseases, and bariatric surgery affect hair health in general and the hair development cycle, and how they influence hair loss.
Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), dexamethasone was to be reduced to 40 mg QD for Days 1-4 of each 28 day-cycle.
The present invention relates to a 1 type phosphatase inhibitor (protein phosphatase 1 inhibitor-2, IPP2) which is a source of marrow stroma cells. The present invention provides polynucleotide for coding molecules of the protein and a method for producing the protein by recombination technology. The present invention also discloses the applications of the 1 type phosphatase inhibitor as a source of marrow stroma cells, and the applications of a polynucleotide coding sequence. The present invention proves that the high expression of the IPP2 can restrict the apoptosis of macrophage RAW264.7. The present invention also discloses the diagnosis and therapeutic strategies of diseases by molecules resisting the protein. The present invention can be particularly used for diagnosing and curing malignant tumors.
OBJECTIVE: While connective tissue graft shrinkage is a well-documented post-transplantation reaction, there is a literature gap concerning hyperplastic tissue response. Despite its infrequent occurrence, investigation is warranted due to its capacity to compromise esthetics, disrupt lip dynamics, and promote food retention. Moreover, efforts to mitigate hyperplastic tissue response often prove challenging, and there is a potential risk of exacerbating gingival tissue rebound.
CLINICAL CONSIDERATIONS: This report presents a potential solution to managing tissue overgrowth after connective tissue grafting in five clinical cases. The patients underwent corrective surgery involving internal excision of excessive tissue while preserving the overlying mucosa. The surgical approach was tailored to excise hyperplastic tissue with minimal trauma, aiming to optimize esthetic outcomes. Subsequent follow-up assessments spanning 1-5 years demonstrated stable results, with no indications of relapse or recurrence of tissue overgrowth.
CONCLUSIONS: Within the limitations of this case series, surgical internal excision holds promise as a viable treatment modality for addressing post-transplantation hyperplastic tissue response.
CLINICAL SIGNIFICANCE: This case series addresses the challenge of uncontrolled tissue overgrowth following connective tissue grafting, a concern for which previous attempts have proven unsuccessful. Internal in-toto excision emerges as a promising approach for effectively eliminating overgrown tissue, offering potential advancements in the clinical management of this complication.
Recently, many clinical studies have showed that HFNC can be successfully used in patients with hypoxemic respiratory failure to improve the comfort, to attenuate respiratory failure and to decrease the rate of tracheal intubation and mortality. Although theoretically HFNC is a potential and ideal treatment for AECOPD patients, the related clinical researches are very few. It still needs to further evaluate the safety and efficacy of HFNC in patients with AECOPD. For moderate AECOPD(pH\<7.35), several guidelines have strongly recommended NPPV as standard therapy, which can reduce the rate of intubation and mortality. A few previous studies have shown that HFNC can efficiently improve alveoli ventilation and breathing pattern in some severe AECOPD patients. Therefore, we hypothesize that HFNC is not inferior to NPPV for preventing endotracheal intubation in moderate AECOPD patients. To assess this hypothesis, we performed a multicenter, randomized, noninferiority trial of HFNV vs NPPV in moderate AECOPD patients.
Compositions, methods for forming compositions, and methods for using compositions for reducing tadpole shrimp populations in temporary pools using the hormone methyl farnesoate. Compositions can include a dry base having a bulk ingredient, a viscous additive having an oily compound, a saline solution, and preparation having an effective amount of phospholipid-encapsulated methyl farnesoate. The composition can be formed by combining the dry base and the viscous additive into a first mixture and adding all or a portion of the saline solution to form a crumbly consistency. Then, the methyl farnesoate preparation can be added. The composition may then be formed into a plurality of particles having shapes and sizes for consumption by the tadpole shrimp. In use, the particles may be dispensed prior to, or immediately after, the temporary pools are flooded with water. The particles may be formed such that they can withstand exposure to water for between about 4 to about 14 days.
An exercise program in the form of home exercise videos will be given to the participants in this group. They will be asked to perform a minimum of two 35-minute exercise sessions per week, over a period of 11 weeks. They will also be required to attend three group exercise sessions, to confirm correct execution of the exercises. A short educational presentation on injury prevention will be offered at the beginning of the study, followed by three informative e-mails over the course of the study.
In multiple sclerosis (MS), alterations of the gut microbiota lead to inflammation. However, the role of other microbiomes in the body in MS has not been fully elucidated. In a pilot case-controlled study, we carried out simultaneous characterization of faecal and oral microbiota and conducted an in-depth analysis of bacterial alterations associated with MS. Using 16S rRNA sequencing and metabolic inference tools, we compared the oral/faecal microbiota and bacterial metabolism pathways in French MS patients (n = 14) and healthy volunteers (HV, n = 21). A classification model based on metabolite flux balance was established and validated in an independent German cohort (MS n = 12, HV n = 38). Our analysis revealed decreases in diversity indices and oral/faecal compartmentalization, the depletion of commensal bacteria (Aggregatibacter and Streptococcus in saliva and Coprobacter and Roseburia in faeces) and enrichment of inflammation-associated bacteria in MS patients (Leptotrichia and Fusobacterium in saliva and Enterobacteriaceae and Actinomyces in faeces). Several microbial pathways were also altered (the polyamine pathway and remodelling of bacterial surface antigens and energetic metabolism) while flux balance analysis revealed associated alterations in metabolite production in MS (nitrogen and nucleoside). Based on this analysis, we identified a specific oral metabolite signature in MS patients, that could discriminate MS patients from HV and rheumatoid arthritis patients. This signature allowed us to create and validate a discrimination model on an independent cohort, which reached a specificity of 92%. Overall, the oral and faecal microbiomes were altered in MS patients. This pilot study highlights the need to study the oral microbiota and oral health implications in patients with autoimmune diseases on a larger scale and suggests that knowledge of the salivary microbiome could help guide the identification of new pathogenic mechanisms associated with the microbiota in MS patients.
Salts of antibiotics, of formula: (where R1=aryl, heteroaryl or heteroarylthio; R2=H or NH2; R3=H or acetoxy) are prepd. by reacting the antibiotics and an amino acid at 0-10 degrees C using water as solvent. When the reaction finishes the soln. is filtered and spray-dried, the temp. of the air on entry being 150-190 degrees C and on leaving 50-90 degrees C, the prod. being further dried by conventional methods.
Conventional pulsed corneal crosslinking; 1 second on, 1 second off; 5.4 J/cm2; 8 mm central treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
COVID-19 survivors often endorse persistent physical and neuropsychiatric problems following disease recovery, a phenomenon described as "long COVID." Research exploring long-COVID continues to evolve in large-scale studies but remains limited among smaller populations (e.g., veterans). We explored the relationship between persistent post-COVID-19 fatigue and cognition among a sample of 246 veterans who voluntarily enrolled in a COVID-19 Convalescence Programme and completed a mental health evaluation of post-illness mood (depression, anxiety, PTSD), cognition (subjective complaints, Modified Telephone Interview for Cognitive Status [TICS-M] performance), fatigue, pain, and sleep. In concert with our hypotheses, subjective cognitive complaints are not significantly correlated with TICS-M performance, but rather are strongly correlated with long-COVID fatigue. Although cognitive changes are common post-COVID complaints, these are likely better predicted by other factors, (e.g., fatigue, mood, pain, and sleep disruption). Furthermore, comorbid mood, sleep, and pain complaints appeared to mediate the relationship between subjective cognitive complaints and fatigue. Limitations to this study included use of retrospective chart review data, limited access to pre-disease data for comparison, and lack of healthy controls. Clinicians should consider the impact of modifiable conditions associated with cognitive and functional decline, as these conditions may be targets for interdisciplinary treatment in a long-COVID veteran population.
2-ethylhexyl diphenyl phosphate (EHDPHP) is a widely used organophosphorus flame retardant and plasticizer, which is commonly found in the environment. EHDPHP not only potentially harms the environment but also causes different degrees of damage to the organism. In this study, the duodenum of chicks was selected as the potential toxic target organ to explore the mechanism of duodenal injury induced by EHDPHP exposure. Ninety one-day-old healthy male chicks were selected and randomly divided into C1(control group), C2(solvent control group), L(800 mg/kg), M(1600 mg/kg), H(3200 mg/kg) according to different doses of EHDPHP after one week of environmental adaptation. The chicks were given continuous gavage for 14 d, 28 d, and 42 d. It was found that constant exposure to EHDPHP caused an increase in duodenal MDA content, a decrease in P-gp, SOD, GSH-Px activities, and a decrease in duodenal mucosal immune factor (sIgA, GSH-Px). The expression of sIgM and mucosal link proteins (CLDN, OCLN, ZO-1, JAM) decreased, and the expression of the inflammatory protein (NF-κB, COX2) in duodenal tissues was up-regulated. The results showed that continuous exposure to EHDPHP could cause duodenal oxidative stress, inflammation, and mucosal barrier damage in chicks, which provided a basis for studying the mechanism of toxic damage caused by EHDPHP in poultry.
Participants will receive a meal plan, based on the recommendations by the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and European Atherosclerosis Society, based on Mediterranean diet pattern with the following macronutrient composition: approximately 15% of calories from animal and vegetable protein, up to 30% of calories from fat, 50-65% from carbohydrates. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.